144 related articles for article (PubMed ID: 35612493)
1. Contribution of G Protein-Coupled Receptor 55 to Periaqueductal Gray-Mediated Antinociception in the Inflammatory Pain.
Blanton H; Armin S; Muenster S; Abood M; Benamar K
Cannabis Cannabinoid Res; 2022 Jun; 7(3):274-278. PubMed ID: 35612493
[TBL] [Abstract][Full Text] [Related]
2. GPR55 in the brain and chronic neuropathic pain.
Armin S; Muenster S; Abood M; Benamar K
Behav Brain Res; 2021 May; 406():113248. PubMed ID: 33745983
[TBL] [Abstract][Full Text] [Related]
3. Medial prefrontal cortex diclofenac-induced antinociception is mediated through GPR55, cannabinoid CB1, and mu-opioid receptors of this area and periaqueductal gray.
Tamaddonfard E; Erfanparast A; Salighedar R; Tamaddonfard S
Naunyn Schmiedebergs Arch Pharmacol; 2020 Mar; 393(3):371-379. PubMed ID: 31641818
[TBL] [Abstract][Full Text] [Related]
4. Blockade of GPR55 in dorsal periaqueductal gray produces anxiety-like behaviors and evocates defensive aggressive responses in alcohol-pre-exposed rats.
Vázquez-León P; Miranda-Páez A; Calvillo-Robledo A; Marichal-Cancino BA
Neurosci Lett; 2021 Nov; 764():136218. PubMed ID: 34487839
[TBL] [Abstract][Full Text] [Related]
5. The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray.
Deliu E; Sperow M; Console-Bram L; Carter RL; Tilley DG; Kalamarides DJ; Kirby LG; Brailoiu GC; Brailoiu E; Benamar K; Abood ME
Mol Pharmacol; 2015 Aug; 88(2):265-72. PubMed ID: 25972448
[TBL] [Abstract][Full Text] [Related]
6. Pain Inhibits Pain: an Ascending-Descending Pain Modulation Pathway Linking Mesolimbic and Classical Descending Mechanisms.
Tobaldini G; Sardi NF; Guilhen VA; Fischer L
Mol Neurobiol; 2019 Feb; 56(2):1000-1013. PubMed ID: 29858776
[TBL] [Abstract][Full Text] [Related]
7. Distribution of CB1 cannabinoid receptors and their relationship with mu-opioid receptors in the rat periaqueductal gray.
Wilson-Poe AR; Morgan MM; Aicher SA; Hegarty DM
Neuroscience; 2012 Jun; 213():191-200. PubMed ID: 22521830
[TBL] [Abstract][Full Text] [Related]
8. Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats.
Esmaeili MH; Reisi Z; Ezzatpanah S; Haghparast A
Eur J Pain; 2016 Nov; 20(10):1753-1762. PubMed ID: 27301294
[TBL] [Abstract][Full Text] [Related]
9. Effects of electrolytic lesion of dorsolateral periaqueductal gray on analgesic response of morphine microinjected into the nucleus cuneiformis in rat.
Haghparast A; Ahmad-Molaei L
Neurosci Lett; 2009 Feb; 451(2):165-9. PubMed ID: 19146915
[TBL] [Abstract][Full Text] [Related]
10. Analgesic effects of cannabinoid receptor agonist WIN55,212-2 in the nucleus cuneiformis in animal models of acute and inflammatory pain in rats.
Ebrahimzadeh M; Haghparast A
Brain Res; 2011 Oct; 1420():19-28. PubMed ID: 21911208
[TBL] [Abstract][Full Text] [Related]
11. Mu-opioid and CB1 cannabinoid receptors of the dorsal periaqueductal gray interplay in the regulation of fear response, but not antinociception.
Godoi MM; Junior HZ; da Cunha JM; Zanoveli JM
Pharmacol Biochem Behav; 2020 Jul; 194():172938. PubMed ID: 32376258
[TBL] [Abstract][Full Text] [Related]
12. Intra-periaqueductal gray matter microinjection of orexin-A decreases formalin-induced nociceptive behaviors in adult male rats.
Azhdari Zarmehri H; Semnanian S; Fathollahi Y; Erami E; Khakpay R; Azizi H; Rohampour K
J Pain; 2011 Feb; 12(2):280-7. PubMed ID: 21145791
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla.
Suplita RL; Farthing JN; Gutierrez T; Hohmann AG
Neuropharmacology; 2005 Dec; 49(8):1201-9. PubMed ID: 16129456
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent plasticity in endocannabinoid modulation of pain processing through postnatal development.
Kwok CH; Devonshire IM; Imraish A; Greenspon CM; Lockwood S; Fielden C; Cooper A; Woodhams S; Sarmad S; Ortori CA; Barrett DA; Kendall D; Bennett AJ; Chapman V; Hathway GJ
Pain; 2017 Nov; 158(11):2222-2232. PubMed ID: 28767505
[TBL] [Abstract][Full Text] [Related]
15. Effects of central neuropeptide S in the mouse formalin test.
Peng YL; Zhang JN; Chang M; Li W; Han RW; Wang R
Peptides; 2010 Oct; 31(10):1878-83. PubMed ID: 20603169
[TBL] [Abstract][Full Text] [Related]
16. GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
Yang H; Zhou J; Lehmann C
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):297-302. PubMed ID: 26669245
[TBL] [Abstract][Full Text] [Related]
17. Supraspinal interaction between HIV-1-gp120 and cannabinoid analgesic effectiveness.
Palma J; Narasimhan M; Guindon J; Benamar K
Naunyn Schmiedebergs Arch Pharmacol; 2018 Oct; 391(10):1157-1161. PubMed ID: 30008083
[TBL] [Abstract][Full Text] [Related]
18. Behavioral evidence linking opioid-sensitive GABAergic neurons in the ventrolateral periaqueductal gray to morphine tolerance.
Morgan MM; Clayton CC; Lane DA
Neuroscience; 2003; 118(1):227-32. PubMed ID: 12676152
[TBL] [Abstract][Full Text] [Related]
19. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Nevalainen T; Irving AJ
Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in the amygdaloid projections to the ventrolateral periaqueductal gray and their activation during inflammatory pain in the rat.
Cantu DJ; Kaur S; Murphy AZ; Averitt DL
J Chem Neuroanat; 2022 Oct; 124():102123. PubMed ID: 35738454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
